Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe.

ABSTRACT:

Introduction

Symptoms of cervical dystonia (CD) can vary in severity and cause significant pain. OnabotulinumtoxinA is an approved treatment for CD. This study assessed health-related quality of life (HRQoL) in patients with CD who received multiple onabotulinumtoxinA treatments.

Methods

This prospective, observational standard-of-care study was conducted at multiple neurology centers in Québec, Canada. Patients reported the health impact of CD using the Cervical Dystonia Impact Profile (CDIP)-58, before and after up to eight onabotulinumtoxinA treatments. Other measures included the Cervical Dystonia Severity Rating Scale by physician, employment status using the Work Productivity Questionnaire and pain using the Pain Numeric Rating Scale (PNRS). Adverse events (AEs) were r

SUBMITTER: Petitclerc M 

PROVIDER: S-EPMC8527835 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature